A Connecticut overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Just under a third of Connecticut adults — 32.0% — have obesity, according to the CDC's 2024 Behavioral Risk Factor Surveillance System (95% CI 30.4–33.6%, n=6,311) 3.
That is a climb from 29.2% in 2020, and the trend has not been flat: 29.2% (2020) → 30.4% (2021) → 30.6% (2022) → 29.4% (2023) → 32.0% (2024) 3.
For Connecticut residents on HUSKY Health, the state's Medicaid program, coverage for these drugs does not exist — not as a prior-authorization hurdle, but as a blanket exclusion. HUSKY's own published pharmacy benefit page lists what the program will not cover, and "drugs to treat obesity" is on that list, alongside cosmetic and fertility drugs 1. The exclusion is scoped to the indication, not the molecule: Wegovy, Zepbound, and Saxenda are all excluded when the diagnosis is obesity, regardless of BMI or comorbidities 1. (GLP-1s prescribed on-label for type 2 diabetes — Ozempic, Mounjaro — appear to sit outside this exclusion, but we found no document that confirms that directly, so treat it as a reasonable inference, not a verified fact.)
KFF's national Medicaid survey, published January 16, 2026 from interviews with state officials conducted in November 2025, corroborates this independently: Connecticut is named as one of seven states — with Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania, and Texas — that cover at least one non-GLP-1 weight-loss drug but zero GLP-1s for obesity. Connecticut is not on KFF's list of the 13 states that do cover GLP-1s for obesity 2.
Neither source carries a policy-change date — HUSKY's page shows no visible "last updated" stamp — so read this as the exclusion's status as of our August 28, 2026 review, not as tied to a specific effective date.
Whatever HUSKY does or does not cover, Astra's price does not move by geography.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
That is the same figure in Hartford, in Waterbury, and in every other state Astra serves. There is no Connecticut markup and no Connecticut discount.
Connecticut currently has 111 federally designated Primary Care Health Professional Shortage Areas, per HRSA's most recent data pull on August 27, 2026 5. Layer on a 5.8% statewide uninsured rate — 211,726 of 3,630,971 residents, per the Census Bureau's 2024 American Community Survey 6 — and a median household income of $96,049, also 2024 ACS 6, and the pattern is a state where affording a specialist visit and finding one nearby are two separate, compounding problems.
Telehealth does not remove the cost barrier, but it removes the distance half of it: a licensed video visit does not care how far the nearest endocrinologist's office is.
Connecticut's telehealth prescribing rules fall under the Connecticut Medical Examining Board, part of the state Department of Public Health (portal.ct.gov/dph).
TODO — not verified in this research pass: confirm current CT-specific telehealth prescribing requirements before this section goes live, including interstate licensure compact participation, any real-time audio-video mandate, and controlled- versus non-controlled-substance prescribing rules.
Astra is licensed to treat patients in all 50 states, Connecticut included. There is no waitlist tied to state of residence.
Astra treats patients in Connecticut through state-licensed physicians.
GLP-1 weight loss in Waterbury, CT — local pricing checked directly against provider websites, next to the same national Astra price listed here.
Astra's price doesn't change by state or city — $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan, the same in Connecticut as everywhere else Astra operates. Whether that beats a specific local clinic depends on the provider; we don't have verified, published statewide Connecticut clinic pricing to compare against here — see the Waterbury page for local pricing where it's been checked directly against provider websites.
No. HUSKY Health’s published pharmacy benefit page lists "drugs to treat obesity" among the drug types it does not cover — a blanket exclusion that applies to Wegovy, Zepbound, and Saxenda regardless of BMI or health history. KFF’s January 2026 national Medicaid survey independently confirms Connecticut as one of seven states covering some other weight-loss drug but no GLP-1s for obesity.
32.0% of Connecticut adults, per the CDC’s 2024 BRFSS survey (95% CI 30.4–33.6%, n=6,311) — up from 29.2% in 2020.
Yes. Astra is licensed to treat patients in all 50 states, including Connecticut, with no waitlist tied to state of residence.
$68/month for semaglutide or $118/month for tirzepatide, billed on a 12-month plan ($816 or $1,416 paid annually) — flat nationwide, no Connecticut-specific pricing.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.